Stock market today: S&P 500 climbs as health care, tech gain; Nvidia earnings loom
SOLANA BEACH, California - Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company with a market capitalization of $3.35 million and trading near $6.12 per share, has secured approximately $1.425 million through a definitive securities purchase agreement for an At-the-Market private placement, according to a press release statement issued Thursday. InvestingPro data shows the company maintains more cash than debt on its balance sheet, though its financial health score indicates challenges ahead.
Under the agreement, the clinical-stage pharmaceutical company will issue 136,844 shares of common stock and 93,179 pre-funded warrants. The deal also includes accompanying warrants to purchase 460,046 shares at $5.82 per share and 230,023 shares at $10.00 per share.
The company indicated that the funding will support the announcement of clinical data from two phase 1 studies for ART26.12 and a phase 2 study readout from the CAReS trial for ART27.13.
As part of the agreement, Artelo will allocate $250,000 of the net proceeds to purchase SOL digital currency, with the remaining funds designated for general corporate and working capital purposes, as well as covering offering-related expenses.
The transaction is expected to close on June 26, 2025, subject to customary closing conditions.
The securities sold in this private placement have not been registered under the Securities Act of 1933 and cannot be resold in the United States without registration or an applicable exemption. Artelo has agreed to file a registration statement covering the resale of these securities.
Artelo Biosciences focuses on developing treatments that modulate lipid-signaling pathways for conditions including cancer, pain, and neurological disorders.
In other recent news, Artelo Biosciences announced a 6-for-1 reverse stock split effective June 13, 2025, as part of its strategy to meet Nasdaq’s minimum bid requirement of $1.00 per share. This corporate action was approved by the company’s board of directors to increase the per-share price, and following the split, Artelo will have approximately 546,667 shares outstanding. D. Boral Capital responded to this development by downgrading Artelo Biosciences from Buy to Hold, citing caution about potential post-split share price pressure and limited near-term upside. Despite the downgrade, Artelo continues to advance its clinical-stage pipeline, presenting promising data at the British Pain Conference. The company showcased its lead FABP5 inhibitor, ART26.12, which demonstrated analgesic effects in models of osteoarthritis pain, comparable to naproxen but with fewer side effects. The first Phase 1 trial results for ART26.12 are expected in the second quarter of 2025, with initial focus on chemotherapy-induced peripheral neuropathy. Artelo Biosciences remains committed to developing therapeutics that address unmet medical needs across various conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.